Vizual Stocks works best vertically on mobile.
VizualStocks APIOperating KPI and segment definitions available for Novo Nordisk (NVO) through the VizualStocks API.
Sales from Novo Nordisk's Region China across obesity, diabetes and rare-disease products. This is the company's China reporting region within International Operations, not revenue from a single drug or therapy area.
chinaRevenueOperating profit from Novo Nordisk's combined Obesity and Diabetes Care segment after the production and operating costs assigned to that business. It measures earnings from the company's GLP-1, insulin and other diabetes and weight-management portfolio before financing and tax.
diabetesAndObesityCareOperatingProfitCombined sales of Novo Nordisk medicines for diabetes and obesity, including GLP-1 products such as Ozempic, Rybelsus and Wegovy, insulin products and other diabetes care. This is the company's dominant therapy-area segment and excludes Rare Disease sales.
diabetesAndObesityCareRevenueSales in the international region stored historically as Europe, Middle East and Africa. Novo Nordisk now reports the corresponding region as EUCAN, meaning Europe and Canada, so values from 2025 onward include Canada and are not directly comparable with the older EMEA scope.
europeMiddleEastAndAfricaRevenueSales of Novo Nordisk diabetes-care products outside GLP-1 medicines and insulin, primarily NovoNorm, injection needles and GlucaGen HypoKit. This residual category completes Total Diabetes Care revenue after the larger product families.
otherDiabetesCareRevenueHistorical sales from Novo Nordisk's North America Operations outside the United States, principally Canada. Novo Nordisk retired this separate category after 2024 and now includes Canada in EUCAN, so it should not carry current-period values.
otherNorthAmericaOperationsRevenueReconciliation adjustment needed to bridge the separately disclosed components of operating profit to the consolidated total during the period.
otherOperatingProfitReconciliationSales of Ozempic, Novo Nordisk's once-weekly injectable semaglutide medicine for adults with type 2 diabetes. The metric excludes oral semaglutide and Wegovy, even though those products use the same active ingredient.
ozempicRevenueOperating profit or loss from Novo Nordisk's Rare Disease segment after the production and operating costs assigned to that business. The segment covers rare blood disorders, rare endocrine disorders and a small group of other rare-disease products.
rareDiseaseOperatingProfitSales from Novo Nordisk's Rare Disease segment, including treatments for haemophilia and other rare blood disorders, growth and endocrine disorders, and other specialty conditions. It excludes the company's much larger diabetes and obesity portfolio.
rareDiseaseRevenueRevenue Novo Nordisk reports for markets outside the separately disclosed regions in its geographic revenue breakdown during the period, measured in Danish kroner.
restOfWorldRevenueSales of Novo Nordisk's oral semaglutide tablet for adults with type 2 diabetes, historically branded Rybelsus and now reported together with Ozempic pill. It excludes injectable Ozempic and obesity-treatment sales from Wegovy pill.
rybelsusRevenueTotal Novo Nordisk sales from diabetes treatment, combining GLP-1 diabetes medicines, insulin products and other diabetes care such as needles and glucagon rescue products. It excludes Wegovy and other medicines sold for obesity treatment.
totalDiabetesCareRevenueSales of Novo Nordisk GLP-1 medicines for type 2 diabetes, including injectable Ozempic and Victoza and oral Ozempic pill/Rybelsus. It excludes Wegovy and other GLP-1 sales classified as obesity care.
totalGlucagonLikePeptide1RevenueSales of Novo Nordisk's insulin portfolio, including long-acting, premix, fast-acting and human insulin products. It excludes GLP-1 diabetes medicines and the company's other non-insulin diabetes products.
totalInsulinRevenueTotal sales of Novo Nordisk medicines for chronic weight management, principally Wegovy injectable, Wegovy pill and the older Saxenda brand. The total is separate from GLP-1 products sold for diabetes even when they use the same active ingredient.
totalObesityCareRevenueNovo Nordisk sales from U.S. Operations across obesity, diabetes and rare-disease medicines. Reported sales can move sharply when the company revises U.S. rebate provisions, so the metric reflects both prescription demand and changes in expected rebates and discounts.
unitedStatesRevenueSales of Victoza, Novo Nordisk's once-daily injectable liraglutide medicine for type 2 diabetes. It is an older GLP-1 brand whose revenue is reported separately from Ozempic and oral semaglutide.
victozaRevenueSales of injectable Wegovy, Novo Nordisk's semaglutide medicine for chronic weight management in people with obesity or overweight. It excludes the oral Wegovy pill and diabetes-branded semaglutide products such as Ozempic and Rybelsus.
wegovyInjectableRevenueSales of Wegovy pill, Novo Nordisk's oral semaglutide medicine for chronic weight management. It is reported separately from injectable Wegovy and from oral semaglutide sold for type 2 diabetes as Ozempic pill/Rybelsus.
wegovyPillRevenue